{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:52:32Z","timestamp":1791355952413,"version":"4.3.1"},"reference-count":44,"publisher":"American Diabetes Association","issue":"5","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,5,1]]},"abstract":"<jats:p>Nondigestible fermentable dietary fibers such as oligofructose (OFS) exert an antidiabetic effect and increase the secretion of glucagon-like peptide 1 (GLP-1). To determine the importance of GLP-1 receptor-dependent mechanisms for the actions of OFS, we studied high-fat-fed diabetic mice treated with OFS for 4 weeks in the presence or absence of the GLP-1 receptor antagonist exendin 9-39 (Ex-9). OFS improved glucose tolerance, fasting blood glucose, glucose-stimulated insulin secretion, and insulin-sensitive hepatic glucose production and reduced body weight gain. Ex-9 totally prevented the beneficial effects of OFS. Furthermore, GLP-1 receptor knockout mice (GLP-1R\u2212\/\u2212) were completely insensitive to the antidiabetic actions of OFS. At the molecular level, the effects of OFS on endogenous glucose production correlated with changes of hepatic IRS (insulin receptor substrate)-2 and Akt phosphorylation in an Ex-9-dependent manner. As inflammation is associated with diabetes and obesity, we quantified nuclear factor-\u03baB and inhibitor of \u03baB kinase \u03b2 in the liver. The activity of both intracellular inflammatory effectors was reduced by OFS but, importantly, this effect could not be reverted by Ex-9. In summary, our data show that the antidiabetic actions of OFS require a functional GLP-1 receptor. These findings highlight the therapeutic potential of enhancing endogenous GLP-1 secretion for the treatment of type 2 diabetes.<\/jats:p>","DOI":"10.2337\/db05-1360","type":"journal-article","created":{"date-parts":[[2006,5,10]],"date-time":"2006-05-10T22:48:46Z","timestamp":1147301326000},"page":"1484-1490","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":350,"title":["Improvement of Glucose Tolerance and Hepatic Insulin Sensitivity by Oligofructose Requires a Functional Glucagon-Like Peptide 1 Receptor"],"prefix":"10.2337","volume":"55","author":[{"given":"Patrice D.","family":"Cani","sequence":"first","affiliation":[{"name":"Unite\u0301 Mixte de Recherche (UMR), Centre National De La Recherche Scientifique, University Paul Sabatier, Toulouse, France"},{"name":"Unit of Pharmacokinetics, Metabolism, Nutrition and Toxicology, Universite\u0301 catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Knauf","sequence":"additional","affiliation":[{"name":"Unite\u0301 Mixte de Recherche (UMR), Centre National De La Recherche Scientifique, University Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Iglesias","sequence":"additional","affiliation":[{"name":"Unite\u0301 Mixte de Recherche (UMR), Centre National De La Recherche Scientifique, University Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Drucker","sequence":"additional","affiliation":[{"name":"Banting and Best Diabetes Centre, Toronto General Hospital, University of Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie M.","family":"Delzenne","sequence":"additional","affiliation":[{"name":"Unit of Pharmacokinetics, Metabolism, Nutrition and Toxicology, Universite\u0301 catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Re\u0301my","family":"Burcelin","sequence":"additional","affiliation":[{"name":"Unite\u0301 Mixte de Recherche (UMR), Centre National De La Recherche Scientifique, University Paul Sabatier, Toulouse, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031207512345900_R1","doi-asserted-by":"crossref","unstructured":"Parillo M, Riccardi G: Diet composition and the risk of type 2 diabetes: epidemiological and clinical evidence. Br J Nutr\u200892: 7\u201319,2004","DOI":"10.1079\/BJN20041117"},{"key":"2022031207512345900_R2","doi-asserted-by":"crossref","unstructured":"Boden G, Shulman GI: Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest\u200832 (Suppl. 3): 14\u201323,2002","DOI":"10.1046\/j.1365-2362.32.s3.3.x"},{"key":"2022031207512345900_R3","doi-asserted-by":"crossref","unstructured":"Burcelin R, Crivelli V, Dacosta A, Roy-Tirelli A, Thorens B: Heterogeneous metabolic adaptation of C57BL\/6J mice to high-fat diet. Am J Physiol Endocrinol Metab\u2008282: E834\u2013E842,2002","DOI":"10.1152\/ajpendo.00332.2001"},{"key":"2022031207512345900_R4","doi-asserted-by":"crossref","unstructured":"Perseghin G, Petersen K, Shulman GI: Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord\u200827 (Suppl. 3): S6\u2013S11,2003","DOI":"10.1038\/sj.ijo.0802491"},{"key":"2022031207512345900_R5","doi-asserted-by":"crossref","unstructured":"Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest\u2008112: 1821\u20131830,2003","DOI":"10.1172\/JCI200319451"},{"key":"2022031207512345900_R6","doi-asserted-by":"crossref","unstructured":"Hegarty BD, Furler SM, Ye J, Cooney GJ, Kraegen EW: The role of intramuscular lipid in insulin resistance. Acta Physiol Scand\u2008178: 373\u2013383,2003","DOI":"10.1046\/j.1365-201X.2003.01162.x"},{"key":"2022031207512345900_R7","doi-asserted-by":"crossref","unstructured":"Bonner G: Hyperinsulinemia, insulin resistance, and hypertension. J Cardiovasc Pharmacol\u200824 (Suppl. 2): S39\u2013S49,1994","DOI":"10.1097\/00005344-199412001-00007"},{"key":"2022031207512345900_R8","doi-asserted-by":"crossref","unstructured":"Koopmans SJ, Ohman L, Haywood JR, Mandarino LJ, DeFronzo RA: Seven days of euglycemic hyperinsulinemia induces insulin resistance for glucose metabolism but not hypertension, elevated catecholamine levels, or increased sodium retention in conscious normal rats. Diabetes\u200846: 1572\u20131578,1997","DOI":"10.2337\/diabetes.46.10.1572"},{"key":"2022031207512345900_R9","doi-asserted-by":"crossref","unstructured":"Yki-Jarvinen H: Fat in the liver and insulin resistance. Ann Med\u200837: 347\u2013356,2005","DOI":"10.1080\/07853890510037383"},{"key":"2022031207512345900_R10","doi-asserted-by":"crossref","unstructured":"Raz I, Eldor R, Cernea S, Shafrir E: Diabetes: insulin resistance and derangements in lipid metabolism: cure through intervention in fat transport and storage. Diabetes Metab Res Rev\u200821: 3\u201314,2005","DOI":"10.1002\/dmrr.493"},{"key":"2022031207512345900_R11","doi-asserted-by":"crossref","unstructured":"Holst JJ, Gromada J: Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab\u2008287: E199\u2013E206,2004","DOI":"10.1152\/ajpendo.00545.2003"},{"key":"2022031207512345900_R12","doi-asserted-by":"crossref","unstructured":"Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet\u2008359: 824\u2013830,2002","DOI":"10.1016\/S0140-6736(02)07952-7"},{"key":"2022031207512345900_R13","doi-asserted-by":"crossref","unstructured":"Delzenne NM, Williams CM: Prebiotics and lipid metabolism. Curr Opin Lipidol\u200813: 61\u201367,2002","DOI":"10.1097\/00041433-200202000-00009"},{"key":"2022031207512345900_R14","doi-asserted-by":"crossref","unstructured":"Piche T, des Varannes SB, Sacher-Huvelin S, Holst JJ, Cuber JC, Galmiche JP: Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology\u2008124: 894\u2013902,2003","DOI":"10.1053\/gast.2003.50159"},{"key":"2022031207512345900_R15","doi-asserted-by":"crossref","unstructured":"Cani PD, Joly E, Horsmans Y, Delzenne NM: Oligofructose promotes satiety in healthy human: a pilot study. Eur J Clin Nutr 2005 [Epub ahead of print]","DOI":"10.1038\/sj.ejcn.1602350"},{"key":"2022031207512345900_R16","doi-asserted-by":"crossref","unstructured":"Yamashita K, Itakura M, Kawai K: Effects of fructo-oligosaccharides on blood glucose and serum lipids in diabetics subjects. Nutr Res\u20084: 961\u2013966,1984","DOI":"10.1016\/S0271-5317(84)80075-5"},{"key":"2022031207512345900_R17","doi-asserted-by":"crossref","unstructured":"Cani PD, Neyrinck AM, Maton N, Delzenne NM: Oligofructose promotes satiety in rats fed a high-fat diet: involvement of glucagon-like peptide-1. Obes Res\u200813: 1000\u20131007,2005","DOI":"10.1038\/oby.2005.117"},{"key":"2022031207512345900_R18","doi-asserted-by":"crossref","unstructured":"Cani PD, Daubioul CA, Reusens B, Remacle C, Catillon G, Delzenne NM: Involvement of endogenous glucagon-like peptide-1(7-36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats. J Endocrinol\u2008185: 457\u2013465,2005","DOI":"10.1677\/joe.1.06100"},{"key":"2022031207512345900_R19","doi-asserted-by":"crossref","unstructured":"Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, Drucker DJ: Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med\u20082: 1254\u20131258,1996","DOI":"10.1038\/nm1196-1254"},{"key":"2022031207512345900_R20","doi-asserted-by":"crossref","unstructured":"Knauf C, Cani PD, Perrin C, Iglesias MA, Maury J, Bernard E, Benhamed F, Gremeaux T, Drucker DJ, Kahn CR, Girard J, Tanti J, Delzenne NM, Postic C, Burcelin R: Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest\u2008112: 3554\u20133563,2005","DOI":"10.1172\/JCI25764"},{"key":"2022031207512345900_R21","doi-asserted-by":"crossref","unstructured":"Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA: Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem\u2008274: 305\u2013315,1999","DOI":"10.1074\/jbc.274.1.305"},{"key":"2022031207512345900_R22","doi-asserted-by":"crossref","unstructured":"Defronzo R, Simonson D, Ferannini E: Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dedendent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia\u200823: 313\u2013319,1982","DOI":"10.1007\/BF00253736"},{"key":"2022031207512345900_R23","doi-asserted-by":"crossref","unstructured":"Pickup JC, Crook MA: Is type II diabetes mellitus a disease of the innate immune system?Diabetologia\u200841: 1241\u20131248,1998","DOI":"10.1007\/s001250051058"},{"key":"2022031207512345900_R24","doi-asserted-by":"crossref","unstructured":"Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE: Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med\u200811: 183\u2013190,2005","DOI":"10.1038\/nm1166"},{"key":"2022031207512345900_R25","doi-asserted-by":"crossref","unstructured":"Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M: IKK-beta links inflammation to obesity-induced insulin resistance. Nat Med\u200811: 191\u2013198,2005","DOI":"10.1038\/nm1185"},{"key":"2022031207512345900_R26","doi-asserted-by":"crossref","unstructured":"Rohl M, Pasparakis M, Baudler S, Baumgartl J, Gautam D, Huth M, De Lorenzi R, Krone W, Rajewsky K, Bruning JC: Conditional disruption of IkappaB kinase 2 fails to prevent obesity-induced insulin resistance. J Clin Invest\u2008113: 474\u2013481,2004","DOI":"10.1172\/JCI200418712"},{"key":"2022031207512345900_R27","doi-asserted-by":"crossref","unstructured":"Scrocchi LA, Drucker DJ: Effects of aging and a high fat diet on body weight and glucose tolerance in glucagon-like peptide-1 receptor(-\/-) mice. Endocrinology\u2008139: 3127\u20133132,1998","DOI":"10.1210\/endo.139.7.6092"},{"key":"2022031207512345900_R28","doi-asserted-by":"crossref","unstructured":"Flamez D, Van Breusegem A, Scrocchi LA, Quartier E, Pipeleers D, Drucker DJ, Schuit F: Mouse pancreatic \u03b2-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene. Diabetes\u200847: 646\u2013652,1998","DOI":"10.2337\/diabetes.47.4.646"},{"key":"2022031207512345900_R29","doi-asserted-by":"crossref","unstructured":"Pederson RA, Satkunarajah M, McIntosh CHS, Scrocchi LA, Flamez D, Schuit F, Drucker DJ, Wheeler MB: Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor\u2212\/\u2212 mice. Diabetes\u200847: 1046\u20131052,1998","DOI":"10.2337\/diabetes.47.7.1046"},{"key":"2022031207512345900_R30","doi-asserted-by":"crossref","unstructured":"Vella A, Rizza RA: Extrapancreatic effects of GIP and GLP-1. Horm Metab Res\u200836: 830\u2013836,2004","DOI":"10.1055\/s-2004-82617"},{"key":"2022031207512345900_R31","doi-asserted-by":"crossref","unstructured":"Burcelin R: The incretins: a link between nutrients and well-being. Br J Nutr\u200893 (Suppl. 1): S147\u2013S156,2005","DOI":"10.1079\/BJN20041340"},{"key":"2022031207512345900_R32","doi-asserted-by":"crossref","unstructured":"Ahren B: Sensory nerves contribute to insulin secretion by glucagon-like peptide-1 in mice. Am J Physiol Regul Integr Comp Physiol\u2008286: R269\u2013R272,2004","DOI":"10.1152\/ajpregu.00423.2003"},{"key":"2022031207512345900_R33","doi-asserted-by":"crossref","unstructured":"Burcelin R, Da Costa A, Drucker D, Thorens B: Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes\u200850: 1720\u20131728,2001","DOI":"10.2337\/diabetes.50.8.1720"},{"key":"2022031207512345900_R34","doi-asserted-by":"crossref","unstructured":"Ionut V, Hucking K, Liberty IF, Bergman RN: Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia\u200848: 967\u2013975,2005","DOI":"10.1007\/s00125-005-1709-3"},{"key":"2022031207512345900_R35","doi-asserted-by":"crossref","unstructured":"Dardevet D, Moore MC, Neal D, DiCostanzo CA, Snead W, Cherrington AD: Insulin-independent effects of GLP-1 on canine liver glucose metabolism: duration of infusion and involvement of hepatoportal region. Am J Physiol Endocrinol Metab\u2008287: E75\u2013E81,2004","DOI":"10.1152\/ajpendo.00035.2004"},{"key":"2022031207512345900_R36","doi-asserted-by":"crossref","unstructured":"Dardevet D, Moore MC, DiCostanzo CA, Farmer B, Neal DW, Snead W, Lautz M, Cherrington AD: Insulin secretion-independent effects of glucagon-like peptide 1 (GLP-1) on canine liver glucose metabolism do not involve portal vein GLP-1 receptors. Am J Physiol Gastrointest Liver Physiol\u2008289: G806\u2013G814,2005","DOI":"10.1152\/ajpgi.00121.2005"},{"key":"2022031207512345900_R37","doi-asserted-by":"crossref","unstructured":"Balkan B, Li X: Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp Physiol\u2008279: R1449\u2013R1454,2000","DOI":"10.1152\/ajpregu.2000.279.4.R1449"},{"key":"2022031207512345900_R38","doi-asserted-by":"crossref","unstructured":"Nakabayashi H, Nishizawa M, Nakagawa A, Takeda R, Niijima A: Vagal hepatopancreatic reflex effect evoked by intraportal appearance of tGLP-1. Am J Physiol\u2008271: E808\u2013E813,1996","DOI":"10.1152\/ajpendo.1996.271.5.E808"},{"key":"2022031207512345900_R39","doi-asserted-by":"crossref","unstructured":"Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ: Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia\u200841: 271\u2013278,1998","DOI":"10.1007\/s001250050903"},{"key":"2022031207512345900_R40","doi-asserted-by":"crossref","unstructured":"Turton MD, O\u2019Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR: A role for glucagon-like peptide-1 in the central regulation of feeding. Nature\u2008379: 69\u201372,1996","DOI":"10.1038\/379069a0"},{"key":"2022031207512345900_R41","doi-asserted-by":"crossref","unstructured":"Van Dijk G, Lindskog S, Holst JJ, Steffens AB, Ahren B: Effects of glucagon-like peptide-I on glucose turnover in rats. Am J Physiol\u2008270: E1015\u2013E1021,1996","DOI":"10.1152\/ajpendo.1996.270.6.E1015"},{"key":"2022031207512345900_R42","doi-asserted-by":"crossref","unstructured":"Rodriquez, dF, Navarro M, Alvarez E, Roncero I, Chowen JA, Maestre O, Gomez R, Munoz RM, Eng J, Blazquez E: Peripheral versus central effects of glucagon-like peptide-1 receptor agonists on satiety and body weight loss in Zucker obese rats. Metabolism\u200849: 709\u2013717,2000","DOI":"10.1053\/meta.2000.6251"},{"key":"2022031207512345900_R43","doi-asserted-by":"crossref","unstructured":"Meeran K, O\u2019Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatei MA, Bloom SR: Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology\u2008140: 244\u2013250,1999","DOI":"10.1210\/endo.140.1.6421"},{"key":"2022031207512345900_R44","doi-asserted-by":"crossref","unstructured":"Neyrinck AM, Alexiou H, Delzenne NM: Kupffer cell activity is involved in the hepatoprotective effect of dietary oligofructose in rats with endotoxic shock. J Nutr\u2008134: 1124\u20131129,2004","DOI":"10.1093\/jn\/134.5.1124"}],"container-title":["Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.org\/diabetes\/diabetes\/article-pdf\/55\/5\/1484\/658699\/zdb00506001484.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article-pdf\/55\/5\/1484\/658699\/zdb00506001484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T16:05:57Z","timestamp":1667405157000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/diabetes\/article\/55\/5\/1484\/12928\/Improvement-of-Glucose-Tolerance-and-Hepatic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5,1]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/db05-1360","relation":{},"ISSN":["0012-1797","1939-327X"],"issn-type":[{"value":"0012-1797","type":"print"},{"value":"1939-327X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,1]]}}}